JP2021506878A5 - - Google Patents

Info

Publication number
JP2021506878A5
JP2021506878A5 JP2020533847A JP2020533847A JP2021506878A5 JP 2021506878 A5 JP2021506878 A5 JP 2021506878A5 JP 2020533847 A JP2020533847 A JP 2020533847A JP 2020533847 A JP2020533847 A JP 2020533847A JP 2021506878 A5 JP2021506878 A5 JP 2021506878A5
Authority
JP
Japan
Prior art keywords
methyl
amino
alkyl
oxy
cyclohexane
Prior art date
Application number
JP2020533847A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019126086A5 (https=
JP7526096B2 (ja
JP2021506878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/066111 external-priority patent/WO2019126086A1/en
Publication of JP2021506878A publication Critical patent/JP2021506878A/ja
Publication of JPWO2019126086A5 publication Critical patent/JPWO2019126086A5/ja
Publication of JP2021506878A5 publication Critical patent/JP2021506878A5/ja
Application granted granted Critical
Publication of JP7526096B2 publication Critical patent/JP7526096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020533847A 2017-12-19 2018-12-18 Lpaアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン Active JP7526096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607398P 2017-12-19 2017-12-19
US62/607,398 2017-12-19
PCT/US2018/066111 WO2019126086A1 (en) 2017-12-19 2018-12-18 Cyclohexyl acid isoxazole azines as lpa antagonists

Publications (4)

Publication Number Publication Date
JP2021506878A JP2021506878A (ja) 2021-02-22
JPWO2019126086A5 JPWO2019126086A5 (https=) 2022-01-31
JP2021506878A5 true JP2021506878A5 (https=) 2022-01-31
JP7526096B2 JP7526096B2 (ja) 2024-07-31

Family

ID=65003576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020533847A Active JP7526096B2 (ja) 2017-12-19 2018-12-18 Lpaアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン

Country Status (7)

Country Link
US (1) US11319309B2 (https=)
EP (1) EP3728209B1 (https=)
JP (1) JP7526096B2 (https=)
KR (1) KR102828422B1 (https=)
CN (1) CN111479807B (https=)
ES (1) ES3058680T3 (https=)
WO (1) WO2019126086A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126089A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
CN114746425A (zh) 2019-12-12 2022-07-12 奇斯药制品公司 作为lpa受体2抑制剂的噻吩并嘧啶衍生物
WO2021116259A1 (en) 2019-12-12 2021-06-17 Chiesi Farmaceutici S.P.A. Aromatic amido derivatives as lpa receptor 2 inhibitors
JP2023505704A (ja) 2019-12-12 2023-02-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Lpa受容体2阻害剤としてのキナゾリン誘導体
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022013378A1 (en) 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
JP2024512557A (ja) 2021-03-24 2024-03-19 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Lpa受容体2阻害物質としての8-シクロ-置換キナゾリン誘導体
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023118253A1 (en) 2021-12-23 2023-06-29 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
EP4490150A1 (en) 2022-03-08 2025-01-15 Chiesi Farmaceutici S.p.A. Amido cyclopropyl derivatives as lpa receptor inhibitors
AU2023238460A1 (en) * 2022-03-25 2024-10-31 Vasthera Co., Ltd. 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
WO2026005060A1 (ja) * 2024-06-28 2026-01-02 三菱ケミカル株式会社 化合物、その化合物の製造方法、その化合物を含む感光性組成物、その組成物を用いたパターン形成方法、基板及び基板の製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) * 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
SG11201407228PA (en) * 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
UA109868C2 (ru) * 2012-06-20 2015-10-12 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Similar Documents

Publication Publication Date Title
JP2021506878A5 (https=)
JPWO2019126086A5 (https=)
JP2021507895A5 (https=)
JP2021508686A5 (https=)
JP2021507896A5 (https=)
JP2021507900A5 (https=)
IL275348B2 (en) Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists
JP5944497B2 (ja) ヘテロシクリルアミノイミダゾピリダジン
JP6534675B2 (ja) mIDH1阻害剤としてのベンズイミダゾール−2−アミン
JP2019530669A5 (https=)
CN103608350B (zh) 三唑并吡啶类化合物
JP6783756B2 (ja) mIDH1阻害剤としてのベンゾイミダゾール−2−アミン
JP6824952B2 (ja) mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール
JP6147761B2 (ja) アミノ置換イミダゾピリダジン
JP2019094350A (ja) 抗癌活性及び抗増殖活性を呈する2−アミノピリミジン−6−オン及び類似体
JP2018534326A5 (https=)
CN102753547A (zh) 三唑并吡啶衍生物
JP2016514719A5 (https=)
JP2018529739A5 (https=)
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
JPWO2019126099A5 (https=)
JP2011523945A5 (https=)
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
JPWO2019126085A5 (https=)
JP2016506959A5 (https=)